Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

著录项

• 来源
  《The European journal of health economics: HEPAC : health economics in prevention and care》 |2020年第2期|219-233|共15页
• 作者

  M. Campioni; I. Agirrezabal; R. HajekJ. MinarikL. PourI. SpickaS. Gonzalez-McQuireP. JandovaV. Maisnar;

  展开▼
• 作者单位

  5grid.4491.80000 0004 1937 116XDepartment of Internal MedicineCharles University in Prague, First;

  1grid.476152.30000 0004 0476 2707Economic Modeling Center of Excellence, Global Health Economics;

  2grid.412684.d0000 0001 2155 4545Department of Haematooncology, University Hospital Ostrava and3grid.10979.360000 0001 1245 3953Department of Hemato-Oncology, University Hospital Olomouc and4grid.412554.30000 0004 0609 2751Department of Internal Medicine, Hematology and OncologyUniversity6grid.476152.30000 0004 0476 2707Global Health Economics, Amgen (Europe) GmbHZugSwitzerland7Amgen s.r.oPragueCzech Republic;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 英语
• 中图分类 保健组织与事业（卫生事业管理）;
• 关键词

  Carfilzomib; Multiple myeloma; Cost-effectiveness; Real world; ASPIRE; Registry of Monoclonal Gammopathies; I19;